No headlines found.
PRNewswire (Thu, 4-Jun 8:00 AM ET)
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
PRNewswire (Tue, 19-May 8:00 AM ET)
Globe Newswire (Tue, 19-May 4:00 AM ET)
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
PRNewswire (Mon, 18-May 8:00 AM ET)
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
PRNewswire (Thu, 7-May 4:05 PM ET)
Globe Newswire (Mon, 6-Apr 7:56 AM ET)
PRNewswire (Thu, 2-Apr 8:00 AM ET)
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Lipocine trades on the NASDAQ stock market under the symbol LPCN.
As of June 18, 2026, LPCN stock price declined to $2.33 with 120,085 million shares trading.
LPCN has a beta of -1.51, meaning it tends to be less sensitive to market movements. LPCN has a correlation of 0.01 to the broad based SPY ETF.
LPCN has a market cap of $19.21 million. This is considered a Sub-Micro Cap stock.
Last quarter Lipocine reported $119,397 in Revenue and -$.54 earnings per share. This fell short of revenue expectation by $-30,603 and missed earnings estimates by -$.05.
In the last 3 years, LPCN traded as high as $12.37 and as low as $1.81.
The top ETF exchange traded funds that LPCN belongs to (by Net Assets): VTI, VXF, DFAS, DCOR, DFMC.
LPCN has underperformed the market in the last year with a return of -27.3%, while the SPY ETF gained +26.9%. In the last 3 month period, LPCN fell short of the market, returning -68.1%, while SPY returned +13.5%. However, in the most recent 2 weeks LPCN has outperformed the stock market by returning +5.4%, while SPY returned -1.1%.
LPCN support price is $2.23 and resistance is $2.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LPCN shares will trade within this expected range on the day.
